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bleak. The papers we publish this week aim to show 
why withdrawing from multilateralism would be the 
wrong response to Ebola. It is perfectly understandable 
why many nations view threats to their citizens and 
sovereignty as reasons to act alone, on the basis of a 
narrow concept of strengthened state security. But 
human beings have many aﬃ  liations and interests. 
We are not deﬁ ned only as citizens of a single nation-
state. To reach a fuller and richer understanding of 
health security, governments, development agencies, 
and health organisations might also argue that each of 
us has an aﬃ  liation to the larger world we inhabit—a 
global identity that demands global solutions through 
cooperation between nations. Global health security, 
we think, is an idea that presses the case in favour of a 
renaissance in multilateralism, not its demise.
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The decline of a woman’s natural hormones during 
menopause is associated with various symptoms, 
including hot ﬂ ashes, night sweats, mood swings, 
and trouble concentrating. Long-term eﬀ ects can 
include bone loss, risk of fractures, and cardiovascular 
disease. To ameliorate short-term and long-term 
consequences of menopause, hormone replacement 
with oestrogen was introduced in the 1940s. The 
biological mechanisms underlying the associations 
between hormone use and various conditions are not 
well understood. Evidence for beneﬁ ts and adverse 
eﬀ ects of menopausal hormone therapy has come 
from many observational studies and a few clinical 
trials.
In the 1970s, observational studies showed a 
strong increase in endometrial cancer risk related 
to postmenopausal oestrogen use.1 As a result, 
oestrogen-progestagen regimens were developed 
to mitigate the increased risk. During the 1990s, 
epidemiological studies showed evidence for an 
increase in breast cancer risk related to oestrogen-
progestagen use.2 In 2002, the Women’s Health 
Initiative randomised trial of oestrogen-progestagen 
versus placebo was stopped early because it 
conﬁ rmed this increased breast cancer risk and, 
somewhat unexpectedly, showed an increase in 
cardiovascular disease among hormone users.3 
Oestrogen-progestagen sales decreased precipitously 
in the following year. Additional analyses from the 
trial showed increased risk of myocardial infarction 
restricted to women who used oestrogen-progestagen 
beyond menopause; furthermore, several adverse 
eﬀ ects increased with hormone therapy use after 
menopause in extended follow-up.4 Currently 
recommended indications for hormone therapy use 
are restricted to treatment of menopausal symptoms, 
not for prevention of chronic disease.5
Regulatory decisions and public health recom-
mendations related to hormone therapy use were 
based mostly on ﬁ ndings from the Women’s Health 
Initiative trial. However, reliance on one trial alone has 
limitations; this trial was not powered to assess rare 
endpoints such as ovarian cancer, and, furthermore, 
the trial was mainly designed to assess short-term 
use and short-term health eﬀ ects. Since early 2000, 
ﬁ ndings from observational studies have suggested 
that long-duration hormone therapy use is associated 
with ovarian cancer risk.6
In The Lancet, the Collaborative Group on 
Epidemiological Studies of Ovarian Cancer7 reports 
ﬁ ndings from a meta-analysis of individual participant 
data from 52 epidemiological studies assessing 
hormone therapy use and ovarian cancer risk. The 
principal analyses involved data from 17 prospective 
studies. The investigators report increased risk with 
current hormone therapy use (for duration <5 years, 
relative risk [RR] 1·43 [95% CI 1·31–1·56]; duration 
≥5 years, 1·41 [1·34–1·49]). Women who reported 
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stopping after having used hormone therapy for 5 years 
or longer (median duration about 10 years) remained 
at elevated risk for some time after stopping (<5 years 
since last use, RR 1·29 [95% CI 1·11–1·49]; ≥5 years 
since last use, 1·10 [1·01–1·20]). Women who reported 
stopping after having used hormone therapy for less 
than 5 years (median duration of use only 1 year) did 
not, however, seem to be at increased risk (<5 years 
since last use, RR 1·17 [95% CI 0·98–1·38]; ≥5 years since 
last use, 0·94 [0·88–1·02]).
These ﬁ ndings support the addition of ovarian cancer 
to the list of adverse eﬀ ects associated with hormone 
therapy use. However, compared with cardiovascular 
diseases and breast cancer, ovarian cancer is far less 
common, suggesting that overall risk assessment of 
hormone therapy will not be strongly aﬀ ected by these 
results. Since the announcement of the Women’s Health 
Initiative ﬁ ndings, the use of hormone therapy has 
dropped substantially, and in the USA use of low-dose 
regimens is more prevalent than use of standard-dose 
and high-dose regimens.8 The present study did 
not evaluate dose, and median year of diagnosis 
was 2001 for the cohort studies—slightly before the 
widespread change in use patterns occurred. In view 
of recommendations to use the lowest dose possible 
for the shortest duration, the study ﬁ ndings did show 
signiﬁ cant increases in ovarian cancer risk even among 
current short-term users (median duration 3 years), 
but a few years after stopping short-term use (after, 
however, a median of only 1 year of use) the risks were 
no longer increased. It is unclear to what extent the 
diﬀ erences in median duration of use between current 
and previous users are responsible for these disparate 
ﬁ ndings. Further, it remains to be explored to what 
extent risk is reduced for low-dose regimens and non-
oral formulations.
Assessment of the association between hormone use 
and women’s cancers can provide important insights 
into hormone-driven carcinogenesis. Importantly, 
oestrogen-progestagen reduced endometrial cancer 
risk compared with oestrogen alone, whereas risk 
was unchanged for ovarian cancer, and much higher 
for breast cancer,9–11 suggesting that progestagen 
has tumour-promoting eﬀ ects in the breast but 
mitigates tumour-promoting eﬀ ects of oestrogen on 
the endometrium. The almost immediate decrease 
in incidence of breast and ovarian cancer after 
announcement of the Women’s Health Initiative results 
and subsequent fall in oestrogen-progestagen use12 
supports an important role of hormone therapy in 
the late stages of carcinogenesis. The results from the 
accompanying study7 are consistent with this notion, 
because ovarian cancer risk fell almost to baseline about 
5 years after cessation of short-duration use (although 
some increased risk remained more than 5 years after 
discontinuation of lengthy use).
At all three cancer sites, hormone use showed 
subtype-speciﬁ c associations with cancer risk, 
underlining the need for well-powered, subtype-speciﬁ c 
studies of hormone therapy use. Importantly, hormone 
therapy use was associated with only serous and 
endometrioid ovarian cancers. With the exception of the 
inverse association with oral contraceptive use, very few 
risk factors have emerged for serous ovarian cancer, the 
most common and most lethal subtype; therefore, any 
reduction in risk, for example by avoidance of hormone 
therapy use, could lead to relevant reductions in ovarian 
cancer mortality.
The available data for breast cancer and 
cardiovascular outcomes from clinical trials and 
observational data dictate caution in the use of 
hormone therapy. In the context of the observational 
data presented in this study,7 it is still not clear whether 
the current recommendation to use hormone therapy 
for the shortest duration possible is appropriate 
for women who are concerned about an increased 
risk of ovarian cancer. The current report underlines 
the importance and limitations of observational 
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The aim of palliative therapy in oncology is to prolong 
life and maintain quality of life for patients, with 
the least therapy necessary to control disease. The 
improvement in overall survival seen in metastatic 
colorectal cancer over the past decade is intrinsically 
associated with the increased number of active 
drugs in the management of disease, and a better 
understanding of how best to use these drugs.1 The 
availability of improved supportive care, less toxic 
regimens, and targeted drugs have led to a shift in the 
treatment paradigm. Previously, oncologists commonly 
used a ﬁ xed number of initial chemotherapy cycles or 
treatment to best response, followed by a complete 
treatment-free interval. Now, the emphasis has shifted 
toward prolonged duration of therapy to control cancer 
growth in the longer term.
However, one of the most commonly used treatments 
in the ﬁ rst-line setting in metastatic colorectal cancer, 
a combination of oxaliplatin and ﬂ uoropyrimidine, 
does not lend itself to prolonged treatment because 
of cumulative neurotoxic eﬀ ects of oxaliplatin. Results 
from trials with an oxaliplatin-based therapy have 
consistently shown that more patients come oﬀ  therapy 
because of toxic eﬀ ects than because of progressive 
disease.2,3 This issue is accentuated when a drug such as 
bevacizumab is added, which can further prolong time 
to tumour progression.
Findings from a detailed analysis of one of the 
largest trials of ﬁ rst-line therapy with a combination 
of bevacizumab, ﬂ uoropyrimidine, and oxaliplatin 
in metastatic colorectal cancer showed that patients 
who received treatment until tumour progression 
obtained the greatest beneﬁ t of anti-VEGF treatment 
with bevacizumab.3 Additionally, ﬁ ndings from several 
phase 3 studies have conﬁ rmed that prolonged duration 
of anti-VEGF treatment, even beyond RECIST-deﬁ ned 
tumour progression, is associated with improved 
outcomes in metastatic colorectal cancer.4,5 Thus, if 
an oxaliplatin-based ﬁ rst-line therapy is used, and 
one emphasis of ﬁ rst-line therapy is to optimise and 
maximise duration of treatment to provide prolonged 
tumour control, a strategy has to be developed to 
pre-emptively deal with the issue of oxaliplatin’s 
cumulative neurotoxic eﬀ ects.
Several trials have investigated the role of 
maintenance therapy in metastatic colorectal 
When less is more: maintenance therapy in colorectal cancer
data for rare and long-term outcomes, especially 
for the complex associations between regimen, 
dose, duration, route of administration, and timing 
of hormone therapy use with ovarian, breast, and 
endometrial cancers.
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